News

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

As conference season approaches the last few months of the year, catch up on highlights from NP & PA conferences, including Fall Clinical for PAs and NPs and SDPA Summer.

Learn more about the latest in dermatology from Sheila Fallon Friedlander, MD; Melodie Young, MSN, ANP-c; Raj Chovatiya, MD, PhD, MSCI; Julie Harper, MD; and Matthew Zirwas, MD.

The FDA has set a PDUFA target action date of May 22, 2025.

By offering a wide range of services, dermatologists can provide a holistic approach to skin health.

Understanding comorbidities such as thyroid dysfunction and vitiligo helps to navigate comprehensive care to achieve long-lasting results in alopecia areata treatment.

Review cutaneous signs and symptoms of HAE that may enhance early diagnosis and treatment.

Announcements from both the FDA and the EC were supported by 2 clinical trials that evaluated the safety and efficacy of delgocitinib cream.

Bimzelx was also approved for non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Zelma Chiesa Fuxench, MD, MSCE, FAAD, and Mona Shahriari, MD, FAAD, discuss the lack of research into psoriasis in skin of color, the absence of diversity in clinical trial populations, and where dermatology as a discipline can go from here.

Keep up with the latest headlines in dermatology from the past week, including data on AI versus dermatology residents, permanent makeup and the risk of allergic contact dermatitis, and more.

Catch up on eczema advancements throughout the year, including news on contact dermatitis, chronic hand eczema, and more.

Lim discusses support for underserved communities, including dermatology training for Pacific Island Nations.

Peptides are increasingly used in cosmeceuticals for their ability to enhance cellular communication and functionality in antiaging formulations.

Elyse Love, MD, discusses the role of the program in supporting students with skin conditions the financial support and empowerment necessary for academic success.

Catch up on the latest news on prurigo nodularis advancements in 2024.

Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Hilary Baldwin, MD, emphasized involving patients in the decision-making process to create a personalized and cost-effective plan.

Data was published in the Journal of the American Board of Family Medicine.

In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical clinical presentation.

In her session at Maui Derm NP+PA Fall, Culton also emphasized the importance of accurate and timely diagnosis, as well as upcoming treatment options.

During an interview with Dermatology Times, Zirwas outlined modern allergens such as sulfites, dietary nickel, and acrylates.

Catch up on coverage from the third day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space.

In his signature Maui Derm NP+PA Fall 2024 session, Shapiro discusses the importance of acting quickly when confronted with a patient who has scarring alopecia.

In a session at Maui Derm NP+PA Fall 2024, Julie Harper, MD, ran through 5 key takeaways for providers managing patients with acne, including where the new triple fixed-dose combination treatment falls in the treatment landscape.

Dermavant’s sNDA for tapinarof cream 1% for AD is still under review with the FDA.